NCT06244758View on ClinicalTrials.gov

Finerenone and Renal Oxidative Stress

PHASE3RecruitingINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

January 18, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2025

Conditions
Type2diabetes
Interventions
DRUG

Finerenone 20 MG Oral Tablet

The intervention is administered orally.

DRUG

Placebo

The intervention is administered orally.

Trial Locations (1)

Unknown

RECRUITING

Clinical Research Center Erlangen, Department of Nephrology and Hypertension, University Hospital Erlangen, Erlangen

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

University of Erlangen-Nürnberg Medical School

OTHER

NCT06244758 - Finerenone and Renal Oxidative Stress | Biotech Hunter | Biotech Hunter